Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Niagen Bioscience (NAGE) over the last 10 years, with Sep 2025 value amounting to $64.3 million.

  • Niagen Bioscience's Cash & Equivalents rose 98.44% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 98.44%. This contributed to the annual value of $44.7 million for FY2024, which is 63.44% up from last year.
  • Per Niagen Bioscience's latest filing, its Cash & Equivalents stood at $64.3 million for Q3 2025, which was up 6.31% from $60.5 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Cash & Equivalents peaked at $64.3 million during Q3 2025, and registered a low of $13.3 million during Q3 2022.
  • For the 3-year period, Niagen Bioscience's Cash & Equivalents averaged around $37.9 million, with its median value being $27.9 million (2024).
  • Per our database at Business Quant, Niagen Bioscience's Cash & Equivalents spiked by 228.48% in 2021 and then tumbled by 59.94% in 2022.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Cash & Equivalents stood at $28.2 million in 2021, then dropped by 27.56% to $20.4 million in 2022, then skyrocketed by 33.68% to $27.3 million in 2023, then surged by 63.44% to $44.7 million in 2024, then skyrocketed by 98.44% to $64.3 million in 2025.
  • Its last three reported values are $64.3 million in Q3 2025, $60.5 million for Q2 2025, and $55.6 million during Q1 2025.